EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-SA 4.0

Coexistence of BCR::ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series

Durgadevi Sundaresan, Debadrita Ray, Amarjot Kaur, Charanpreet Singh, Nithye Parvathy, Alpesh Kapadia, Riju Rani Deka, Narender Kumar, Jogeshwar Binota, Pankaj Malhotra, Shano Naseem, Praveen Sharma

Indian Journal of Pathology and Microbiology · 2025

DOI: 10.4103/ijpm.ijpm_240_24 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Indian Journal of Pathology and Microbiology, 2025. Verfasst von Durgadevi Sundaresan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab, India. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Janus Kinase 2, Myeloproliferative Disorders, Proto-Oncogene Proteins c-abl. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BCR::ABL1 translocation and JAK2V617F mutations are canonical variants of myeloproliferative neoplasms (MPNs). Traditionally considered mutually exclusive, they may rarely coexist. We report the clinicopathological profile and treatment outcomes of four MPN patients with coexistence of these disease-defining genetic variants. Both mutations were detected simultaneously in three patients who did not harbor tell-tale signs of CML and were evaluated for both BCR::ABL1 and JAK2V617F based on clues from hemogram, peripheral-blood and bone-marrow examination. All were treated with imatinib and hydroxyurea and attained major molecular response after 2–7 months. In another patient, JAK2V617F was detected 15 years after the diagnosis of CML at the time of evaluation of loss of hematological and molecular response. She was treated with dasatinib but no hematologic or molecular response was attained after 6 months despite good compliance. In conclusion, BCR::ABL1 and JAK2V617F may rarely coexist in MPN with variable temporal evolution, clinicopathological profile, and treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablJanus Kinase 2Myeloproliferative DisordersProto-Oncogene Proteins c-ablProto-Oncogene Proteins c-bcrTranslocation, GeneticFemaleHumansAntineoplastic AgentsHydroxyureaImatinib MesylateIndiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMutationTreatment Outcome

Stichwörter der Autor:innen

MPNchronic myeloid leukemia

Substanzen

ABL1 protein, humanAntineoplastic AgentsFusion Proteins, bcr-ablHydroxyureaImatinib MesylateJAK2 protein, humanJanus Kinase 2Proto-Oncogene Proteins c-ablProto-Oncogene Proteins c-bcr

Autor:innen und Institutionen

  • Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab, India.
  • Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab, India.

Zitieren

APA

Sundaresan, D., Ray, D., Kaur, A., Singh, C., Parvathy, N., Kapadia, A., Deka, R. R., Kumar, N., Binota, J., Malhotra, P., Naseem, S., & Sharma, P. (2025). Coexistence of BCR::ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series. Indian Journal of Pathology and Microbiology. https://doi.org/10.4103/ijpm.ijpm_240_24

Vancouver

Sundaresan D, Ray D, Kaur A, Singh C, Parvathy N, Kapadia A, et al. Coexistence of BCR::ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series. Indian Journal of Pathology and Microbiology. 2025. doi:10.4103/ijpm.ijpm_240_24

BibTeX
@article{Sundaresan2025,
  author = {Sundaresan, Durgadevi and Ray, Debadrita and Kaur, Amarjot and Singh, Charanpreet and Parvathy, Nithye and Kapadia, Alpesh and Deka, Riju Rani and Kumar, Narender and Binota, Jogeshwar and Malhotra, Pankaj and Naseem, Shano and Sharma, Praveen},
  title = {Coexistence of BCR::ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series},
  journal = {Indian Journal of Pathology and Microbiology},
  year = {2025},
  doi = {10.4103/ijpm.ijpm_240_24}
}
Kostenlos starten →